IMCIVREE (setmelanotide) — Regulatory decision
H2 2026
The Company anticipates the Committee for Medicinal Products for Human Use (CHMP) would issue an opinion to the European Commission (EC) in the second quarter of 2026 with potential marketing authorization in the second half of 2026.Source filing